Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-07-30
DOI
10.3389/fimmu.2019.01801
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
- (2019) Kyung Hae Jung et al. CLINICAL CANCER RESEARCH
- Investigation of the Absolute Bioavailability and Human Mass Balance of Navoximod, a Novel IDO1 Inhibitor
- (2019) Shuguang Ma et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Aryl hydrocarbon receptor and intestinal immunity
- (2018) Bruno Lamas et al. Mucosal Immunology
- Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism
- (2018) Jing Gao et al. Frontiers in Cellular and Infection Microbiology
- Kynurenic Acid: The Janus-Faced Role of an Immunomodulatory Tryptophan Metabolite and Its Link to Pathological Conditions
- (2018) Elisa Wirthgen et al. Frontiers in Immunology
- A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma
- (2018) Lukas Krähenbühl et al. NEOPLASIA
- Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
- (2018) Tara C. Mitchell et al. JOURNAL OF CLINICAL ONCOLOGY
- Corrigendum: How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive
- (2018) Alessandro Poggi et al. Frontiers in Immunology
- Effects of 1-Methyltryptophan on Immune Responses and the Kynurenine Pathway after Lipopolysaccharide Challenge in Pigs
- (2018) Elisa Wirthgen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
- (2018) Takefumi Komiya et al. Frontiers in Oncology
- Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor
- (2017) Benjamin J. Moyer et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology
- (2017) Eddy W. Yue et al. ACS Medicinal Chemistry Letters
- The IDO inhibitor 1-methyl tryptophan activates the aryl hydrocarbon receptor response in mesenchymal stromal cells
- (2017) Holly C. Lewis et al. Oncotarget
- Pharmacokinetics of 1-methyl-L-tryptophan after single and repeated subcutaneous application in a porcine model
- (2016) Elisa Wirthgen et al. EXPERIMENTAL ANIMALS
- The Janus-faced nature of IDO1 in infectious diseases: challenges and therapeutic opportunities
- (2016) Francesco Antonio Greco et al. Future Medicinal Chemistry
- Indoleamine 2,3-dioxygenase and regulatory T cells in acute myeloid leukemia
- (2016) Iman Mansour et al. Hematology
- Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies
- (2016) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
- (2016) Caroline Jochems et al. Oncotarget
- Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR
- (2015) Ulrike M. Litzenburger et al. Oncotarget
- A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
- (2015) Hatem H. Soliman et al. Oncotarget
- Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy.
- (2014) Mario R. Mautino et al. CANCER RESEARCH
- Mesenchymal Stem Cells Use IDO to Regulate Immunity in Tumor Microenvironment
- (2014) W. Ling et al. CANCER RESEARCH
- Aryl hydrocarbon receptor control of a disease tolerance defence pathway
- (2014) Alban Bessede et al. NATURE
- Aryl Hydrocarbon Receptor and Kynurenine: Recent Advances in Autoimmune Disease Research
- (2014) Nam Trung Nguyen et al. Frontiers in Immunology
- 6-Formylindolo (3,2-b)carbazole (FICZ) enhances retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells
- (2013) Rodica P Bunaciu et al. Molecular Cancer
- Influence of Tryptophan Contained in 1-Methyl-Tryptophan on Antimicrobial and Immunoregulatory Functions of Indoleamine 2,3-Dioxygenase
- (2012) Silvia K. Schmidt et al. PLoS One
- IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan
- (2012) Richard Metz et al. OncoImmunology
- A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity
- (2011) Huei-Jiun Yang et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- The kynurenine system and immunoregulation
- (2011) Yvette Mándi et al. JOURNAL OF NEURAL TRANSMISSION
- Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
- (2011) Maria T Pallotta et al. NATURE IMMUNOLOGY
- The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
- (2011) Christiane A. Opitz et al. PLoS One
- Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
- (2010) X. Liu et al. BLOOD
- Psychological Stress-Induced, IDO1-Dependent Tryptophan Catabolism: Implications on Immunosuppression in Mice and Humans
- (2010) Cornelia Kiank et al. PLoS One
- Kynurenic Acid Is a Potent Endogenous Aryl Hydrocarbon Receptor Ligand that Synergistically Induces Interleukin-6 in the Presence of Inflammatory Signaling
- (2010) Brett C. DiNatale et al. TOXICOLOGICAL SCIENCES
- Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer
- (2009) Feng Qian et al. CANCER RESEARCH
- Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
- (2009) X. Liu et al. CURRENT CANCER DRUG TARGETS
- Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites
- (2009) W. R. Wikoff et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Kinetic, Spectroscopic, and Redox Study of Human Tryptophan 2,3-Dioxygenase†
- (2008) Jaswir Basran et al. BIOCHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now